New vaccine targets 24 pneumococcal strains in major trial

NCT ID NCT06678620

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Shanghai Reinovax Biologics Co.,LTD Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests a new 24-valent pneumococcal conjugate vaccine (PCV24) in 992 adults aged 18 and older. The study aims to check the vaccine's safety and how well it triggers an immune response compared to an existing 23-valent vaccine. Participants receive one dose of either PCV24 or the comparator vaccine, and researchers monitor side effects and antibody levels for 30 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 24-valent pneumococcal polysaccharide conjugate vaccine (PCV24)
What this could lead to: If successful, this could lead to a vaccine that protects against 24 types of pneumococcal bacteria, potentially preventing serious infections like pneumonia.
What could go wrong: This is an early phase II trial, so the vaccine may not trigger a strong enough immune response or could have unexpected side effects. Results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL INFECTIOUS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PNEUMOCOCCAL INFECTIOUS DISEASE

Contacts and locations

Locations

Pizhou Center for Disease Control and Prevention

Pizhou, Jiangsu, China
Xuzhou Center for Disease Control and Prevention

Xuzhou, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.